Insider Selling: Castle Biosciences, Inc. (NASDAQ:CSTL) Director Sells 7,867 Shares of Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) Director Daniel Bradbury sold 7,867 shares of the business’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $29.44, for a total transaction of $231,604.48. Following the sale, the director now directly owns 5,700 shares in the company, valued at $167,808. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Daniel Bradbury also recently made the following trade(s):

• On Monday, August 12th, Daniel Bradbury sold 7,883 shares of Castle Biosciences stock. The shares were sold at an average price of $26.65, for a total transaction of $210,081.95.

Castle Biosciences Stock Performance

CSTL traded down $1.26 during mid-day trading on Wednesday, reaching $28.75. 488,922 shares of the company traded hands, compared to its average volume of 306,237. The stock has a market capitalization of $793.70 million, a P/E ratio of -24.96 and a beta of 1.03. Castle Biosciences, Inc. has a 52-week low of $12.07 and a 52-week high of $32.53. The company has a quick ratio of 7.92, a current ratio of 8.12 and a debt-to-equity ratio of 0.02. The company’s fifty day moving average price is $28.36 and its 200-day moving average price is $24.03.

Castle Biosciences (NASDAQ:CSTL) last posted its quarterly earnings results on Monday, August 5th. The company reported $0.31 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.47. The business had revenue of $87.00 million during the quarter, compared to analyst estimates of $69.95 million. Castle Biosciences had a negative net margin of 1.08% and a negative return on equity of 0.77%. During the same period in the prior year, the business posted ($0.70) earnings per share. On average, sell-side analysts expect that Castle Biosciences, Inc. will post -0.58 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have commented on the company. Stephens reissued an “overweight” rating and issued a $37.00 target price on shares of Castle Biosciences in a report on Tuesday, August 6th. Robert W. Baird lifted their target price on shares of Castle Biosciences from $34.00 to $37.00 and gave the stock an “outperform” rating in a report on Tuesday, August 6th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $32.80.

Institutional Investors Weigh In On Castle Biosciences

Institutional investors and hedge funds have recently bought and sold shares of the business. RiverPark Advisors LLC grew its holdings in Castle Biosciences by 362.2% during the 1st quarter. RiverPark Advisors LLC now owns 2,861 shares of the company’s stock valued at $63,000 after buying an additional 2,242 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in Castle Biosciences by 70.3% during the first quarter. China Universal Asset Management Co. Ltd. now owns 5,297 shares of the company’s stock valued at $117,000 after acquiring an additional 2,187 shares in the last quarter. Denali Advisors LLC bought a new stake in Castle Biosciences in the 1st quarter valued at $186,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Castle Biosciences by 10.7% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,882 shares of the company’s stock worth $215,000 after purchasing an additional 952 shares in the last quarter. Finally, Birchview Capital LP bought a new position in Castle Biosciences during the fourth quarter valued at approximately $216,000. 92.60% of the stock is owned by institutional investors.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.